Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry
Fremanezumab can be considered a very effective treatment option for preventing migraines in difficult-to-treat women, aged 18-70 years, regardless of their menopausal status.
Authors
- Dimitrios Rikos (ORCID: https://orcid.org/0000-0003-2346-5057)
- Georgia Xiromerisiou (ORCID: https://orcid.org/0000-0001-7162-3588)
- Anna P. Andreou (ORCID: https://orcid.org/0000-0002-7008-6626)
- Panagiotis Soldatos
- Dimitrios Rallis (ORCID: https://orcid.org/0000-0002-5156-0345)
- Michail Vikelis (ORCID: https://orcid.org/0000-0002-2715-7898)
- Andreas A. Argyriou (ORCID: https://orcid.org/0000-0003-2131-7114)
- Pantelis Litsardopoulos
- Emmanouil V. Dermitzakis (ORCID: https://orcid.org/0000-0001-9275-0076)
Institutions
- University of Thessaly (GR)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Agios Andreas Hospital (GR)
- Euromedica (GR)
- Tzaneion General Hospital (GR)
- 404 General Military Hospital (GR)
Publication Details
- Journal
- Expert Review of Neurotherapeutics
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1080/14737175.2024.2403576
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00